Storb R. Bone marrow transplantation. Transplant Proc 1995:27:2649-52.
Champlin R. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation. Hematol Oncol Clin North Am 1990:4:687-98.
Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991:78:2120-30.
Drobyski WR, Ash RC, Casper JT, et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 1994;83:1980-7.
Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998:339:1186-93.
Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988:108:806-14.
Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990:75:555-62.
Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990:76:2462-5.
Bar BM, Schattenberg A, Mensink EJ. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 1993:11:513-9.
Drobyski WR, Keever CA, Roth MS, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993:82:2310-8.
Porter DL, Roth MS, McGarigle C, et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994:330:100-6.
Van Rhee F, Lin F, Cullis JO, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusion before the onset of hematologic relapse. Blood 1994:83:3377-83.
Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995:86:1261-8.
Girt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995:86:4337-43.
Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995:86:2041-50.
Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997:15:433-44.
Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy: the treatment of choice for all hematologic malignancies relapsing post BMT. Blood 1996:87:4011-3.
Szer J, Grigg AP, Phillips GL, Sheridan WP. Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. Bone Marrow Transplant 1993:11:109-12.
Bressoud A, Chapuis B, Roux E, et al. Donor lymphocyte infusion for a patient with relapsing myelodysplastic syndrome after allogeneic bone marrow transplantation. Blood 1996;88:1902-3.
Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997:90:4206-11.
Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma effect: proof of principle. Blood 1996;87:1196-8.
Bernard M, Dauriac C, Drenou B, et al. Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin's lymphoma. Bone Marrow Transplant 1999:23:329-33.
Barnes D, Loutit JF. Treatment of murine leukaemia with X-rays and homologous bone marrow. Br Med J 1956:2:626-7.
Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979;300:1068-73.
Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981:304:1529-33.
Lee M, Khouri I, Champlin R, et al. Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation. Br J Haematol 1992:82:708-14.
Beguin Y, Collignon J, Laurent C, Fillet G. Spontaneous complete remission and recovery of donor haemopoiesis without GVHD after relapse and apparent marrow graft rejection in poor-prognosis myelodysplastic syndrome. Br J Haematol 1996:94:507-9.
Suzuki R, Taji H, Iida S, et al. Complete cytogenetic response with host-derived hematopoiesis induced by cyclosporin: a discontinuation in a patient with relapsed chronic myelogenous leukemia after bone marrow transplantation. Bone Marrow Transplant 1997:20:615-7.
Mehta J, Powles R, Kulkarni S, et al. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients. Bone Marrow Transplant 1997:20:129-35.
Barrett AJ. Mechanisms of the graft-versus-leukemia reaction. Stem Cells 1997:15:248-58.
Asai O, Longo DL, Tian ZG, et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effect by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest 1998:101:1835-42.
Weichold FF, Jiang YZ, Dunn DE, et al. Regulation of a graft-versus-leukemia effect by major histocompatibility complex class II molecules on leukemia cells: HLA-DRl expression renders K562 cell tumors resistant to adoptively transferred lymphocytes in severe combined immunodeficiency mice/nonobese diabetic mice. Blood 1997:90:4553-8.
Delain M, Tiberghien P, Racadot E, et al. Variability of the alloreactive T-cell response to human leukemic blasts. Leukemia 1994:8:642-7.
Faber LM, van der Hoeven J, Goulmy E, et al. Recognition of clnogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CDS+ or CD4+ minor histo-compatibiliry antigen-specific cytotoxic T lymphocytes. J Clin Invest 1995:96:877-83.
Jiang YZ, Mavroudis D, Dermime S, et al. Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. Br J Haematol 1996:93:606-12.
Nimer SD, Giorgi J, Gajewski JL, et al. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial. Transplantation 1994:57:82-7.
Champlin R, Jansen J, Ho W, Reichert T. Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia. Transplant Proc 1991:23:1695-6.
Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995:86:4337-43.
Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998:91:3671-80.
Nagler A, Condiotti R, Nabet C, et al. Selective CD4+ T-cell depletion does not prevent graft-versus-host disease. Transplantation 1998:66:138-41.
Nieda M, Nicol A, Kikuchi A, et al. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood 1998:91:977-83.
Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood 1998:91:2197-207.
Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92:1549-55.
Guinan EC, Gribben JG, Boussiotis VA, et al. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994:84:3261-82.
Matulonis UA, Dosiou C, Lamont C, et al. Role of B7-l in mediating an immune response to myeloid leukemia cells. Blood 1995:85:2507-15.
Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999:94:333-9.
Zeis M, Uharek L, Glass B, et al. Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukaemia effect in mice. Br J Haematol 1997:96:757-61.
Glass B, Uharek L, Zeis M, et al. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells. Br J Haematol 1996;93:412-20.
Keil F, Haas OA, Fritsch G, et al. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood 1997;89:3113-7.
Kolb HJ Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol 1997:9:139-45.
Aker M, Kapelushnik J, Pugatsch T, et al. Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bone marrow transplantation for beta-thalassemia major. J Pediatr Hematol Oncol 1998:20:145-8.
Mutis T, Verdijk R, Schrama E, et al. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999:93:2336-41.
Goulmy E, Schipper R, Pool J, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996:334:281-5.
Mutis T, Gillespie G, Schrama E, et al. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med 1999:5:839-42.
Ten Bosch GJ, Toomvliet AC, Friede T, et al. Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. leukemia 1995:9:1344-8.
Bocchia M, Korontsvit T, Xu Q, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996:87:3587-92.
Osman Y, Takahashi M, Zheng Z, et al. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients, Leukemia 1999:13:166-74.
Yotnda P, Firat H, Garcia-Pons F, et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998:101:2290-6.
Kwak LW, Campbell M, Czerwinski D, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1993:327:1209-15.
Kwak I.W, Taub DD, Duffey PL, et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995:345:1016-20.
Massaia M, Borrione P, Battaglio S, et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 1999:94:673-83.
Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 1999:93:2411-9.
Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996:2:551-5.
Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994:330:1185-91.
Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995:345:9-13.
O'Reilly RJ, Small TN, Papadopoulos E, et al. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 1997:157:195-216.
Sing AP, Ambinder RF, Hong DJ, et al. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Stemberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease. Blood 1997:89:1978-86.
Choudhury A, Gajewski JL, Liang JC, et al. Use of leukemic dendritic cells for the generation of antileukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997;89:1133-42.
Falkenburg JH, Wafelman AR, Joosten P, et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia reactive cytotoxic T lymphocytes. Blood 1999:94:1201-8.
Fuchs EJ, Seber A, Altomonte V, et al. Chemotherapy does not nullify the ability of donor lymphocyte infusions to mediate graft-versus-host reactions. Bone Marrow Transplant 1998:22:303-5.
Dazzi F, Szydlo R, Craddock C, Goldman JM. Adoptive immunotherapy for patients who relapse after allografting for chronic myeloid leukemia: a comparison of two regimens for donor lymphocyte infusion (abstract). Blood 1998;92:653a.
Tiberghien P, Cahn JY, Contassot E, et al. Gene transfer applied to the modulation of alloreactivity. Hematol Cell Ther 1996:38:221-4.
Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997:276:1719-24.
Munshi NC, Govindarajan R, Drake R, et al. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood 1997;89:1334-40.
Marktel S, Ciceri F, Bonini C, Bordignon C. A new suicide system based on gene transfer of Fas into donor lymphocytes for controlled GVL (abstract). Blood 1998;92:667a.
Benyunes MC, Higuchi C, York A, et al. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant 1995;16:283-8.
Slavin S, Ackerstein A, Vourka-Karussis U, et al. Control of relapse due to minimal residual disease (MRD) by cell-mediated cytokine-activated immunotherapy in conjunction with bone marrow transplantation. Baillieres Clin Haematol 1991:4:715-25.
Sullivan KM, Storb R, Buckner CD, Fefer A. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989:320:828-34.
Naparstek E, Nagler A, Or R, et al. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies. In: Cecka JM, Terasaki PI (eds). Clinical transplants, 1996. Los Angeles: UCLA Tissue Typing Laboratory, 1996:281-90.
Barrett Al, Mavroudis D, Tisdale J, et al. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 1998;21:543-51.
Naparstek E, Nagler A, Or R, et al. Donor lymphocyte infusions (DLI) for prevention of leukemic relapse after T-cell depleted marrow transplants (abstract). Blood 1998;92:654a.
Stoppa AM, Aurran T, Chabannon M, Biaise D. Feasibility of CD34+ selected allogeneic bone marrow transplantation (ABMT) followed after 2 months by prophylactic donor lymphocytes infusion (DLI) in high risk hematologic malignancies (abstract). Blood 1998;92:454a.
Smith CA, Ng CY, Heslop HE, et al. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother 1995:4:73-9.
Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med 1994:331:679-80.
Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-63.
Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817-24.
Storb R, Yu C, Sandmaier BM, et al. Mixed hematopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting. Ann N Y Acad Sci 1999:872:375-6.
McSweeney PA, Wagner JL, Maloney DG, et al. Outpatient PBSC allografts using immunosuppression with low-dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant (abstract). Blood 1998;92:519a.
